



Biocon Limited

20th KM, Hosur Road

Electronic City

Bangalore 560 100, India

T 91 80 2808 2808

F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SP/2023-24/118

November 13, 2023

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. '**Biocon Biologics Receives MHRA, UK Approval for YESAFILI[®], Biosimilar Aflibercept**'.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma



Mayank Verma

Company Secretary and Compliance Officer

Membership No.: ACS 18776

Encl: Company Statement

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Biologics Receives MHRA, UK Approval for YESAFILI[®], Biosimilar Aflibercept

Bengaluru, Karnataka, India, November 13, 2023

Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), has announced that MHRA, Medicines and Healthcare products Regulatory Agency in the UK, has granted marketing authorization for YESAFILI[®], a biosimilar of Aflibercept.

In September, YESAFILI[®], received marketing authorization approval from the European Commission (EC) for the European Union (EU).

YESAFILI[®], an ophthalmology product, is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). It is highly similar to the reference product Eylea[®] (aflibercept). Data shows that YESAFILI[®] has comparable quality, safety, and efficacy to Eylea[®].

"We are very pleased to receive the MHRA approval for YESAFILI[®], biosimilar Aflibercept, which will enable us to address the needs of patients impacted by macular degeneration and diabetic retinopathy, in the UK. This approval will expand our biosimilar offerings to patients across the globe, building on our oncology and diabetes product portfolios." – Company Spokesperson

Aflibercept brand sales in UK were USD 790 million (MAT June 2023, IQVIA LC\$*).

YESAFILI[®] is a registered trademark of a BBL company.

(* LC\$ = Local currency sales converted to US dollars at constant exchange rates)

For more information: seema.ahuja@biocon.com